Made in Bangladesh
- Thread starter Bilal9
- Start date
Bilal9
ELITE MEMBER
- Joined
- Feb 4, 2014
- Messages
- 26,569
- Reaction score
- 9
- Country
- Location
Charu Ceramic Industry limited of Bangladesh has signed a memorandum of understanding (MoU) with Siam Sanitary Ware Company Limited of Thailand to produce world famous Cotto brand luxury sanitary-ware in Bangladesh.
(Cotto competes in Asian market with and was inspired by the brand 'Toto', another Japanese luxury sanitary-ware brand - Bilal)
Charu Ceramic, a sister concern of Great Wall Ceramic Ind. Ltd. (one of the larger Bangladeshi tile manufacturers) signed the MoU with Siam Sanitary, the largest sanitary ware manufacturer of Thailand, said a press release.
"To meet Bangladesh's consumer demand for world-class sanitary ware at reasonable price we are going to produce 1.5 Million pieces a year in the country," the press release quoted Charu Ceramic Founder and Managing Director Mohammed Shamsul Huda as stating on the signing of the MoU.
(Cotto competes in Asian market with and was inspired by the brand 'Toto', another Japanese luxury sanitary-ware brand - Bilal)
Charu Ceramic, a sister concern of Great Wall Ceramic Ind. Ltd. (one of the larger Bangladeshi tile manufacturers) signed the MoU with Siam Sanitary, the largest sanitary ware manufacturer of Thailand, said a press release.
"To meet Bangladesh's consumer demand for world-class sanitary ware at reasonable price we are going to produce 1.5 Million pieces a year in the country," the press release quoted Charu Ceramic Founder and Managing Director Mohammed Shamsul Huda as stating on the signing of the MoU.
Bilal9
ELITE MEMBER
- Joined
- Feb 4, 2014
- Messages
- 26,569
- Reaction score
- 9
- Country
- Location
MADE IN BANGLADESH ★ WORLD'S PIONEERING HI-TECH FERRY
Builder - Western Marine Shipyard Limited
Project Name: DKF
Details:
Vessel’s name: ISEFJORD
Owner/Operator: Hundested-Rorvig Faergefart A/S, Denmark
Flag: Danish Maritime Authority
Class: Bureau Veritas
Designer: Jorgen Petersen Ltd & Norman Marine, Denmark
Length OA: 51.00m
Length BP: 50.49m
Breadth moulded: 11.60m
Depth moulded: 3.40m
Gross tonnage: 475
Draught: 2.25m
Deadweight: 165 tons
Lightweight: 469.65 tons
Service Speed: 11 knots @ 85% mcr
Max speed: 14 knots
Range: Coastal area- 20 nm in winter, 15 nm in summer, in tropical zone upto 100 nm
Class Notation:
I +HULL + MACH
RO-RO PASSENGER SHIP
COASTAL AREA
+AUT-UMS, ICE CLASS 1D
Other important international regulations complied as per Danish Maritime Authority
Main engine:
Maker: Cummins
Model: QSK19 MCRs
Number: Two
Output: 375 kw each
Speed: 1800rpm
Propulsion & Steering System:
Maker: Schottel
Model: STP 0330 FP
Steering Type: SCHOTTEL SST 602
Number: Two (aft & forward)
Upper and lower gear box type: SCHOTTEL CYCLO-PALLOID-TYPE GEAR DIAMETER
Gear ratio: 4.042:1
Shafting Arrangement on each propulsion: 2 X Carden Shaft,1x Solid Intermediate Shaft,1x Elastic Coupling
Shafting Length: 4000 Mm (each propulsion)
Propellers
Material: G-CuAI10Fe5Ni5-C (CU 3)
Type: Azimuth propeller
Maker: Schottel
Number: Two (Aft & forward)
Fixed pitch (push/pull system)
Diameter: 1250 mm
Speed: 445 rpm to get 11 knot vessel speed.
Place of Photo: Uden for Hundested Havn. 55.961°, 11.834°
65m Landing Craft for Dubai, United Arab Emirates made by Western Marine
BDforever
ELITE MEMBER
- Joined
- Feb 12, 2013
- Messages
- 14,387
- Reaction score
- 8
- Country
- Location
recently CDDL and Western Marine has signed agreement of co-operation in various field including .... ahem
MADE IN BANGLADESH ★ WORLD'S PIONEERING HI-TECH FERRY
Builder - Western Marine Shipyard Limited
Project Name: DKF
Details:
Vessel’s name: ISEFJORD
Owner/Operator: Hundested-Rorvig Faergefart A/S, Denmark
Flag: Danish Maritime Authority
Class: Bureau Veritas
Designer: Jorgen Petersen Ltd & Norman Marine, Denmark
Length OA: 51.00m
Length BP: 50.49m
Breadth moulded: 11.60m
Depth moulded: 3.40m
Gross tonnage: 475
Draught: 2.25m
Deadweight: 165 tons
Lightweight: 469.65 tons
Service Speed: 11 knots @ 85% mcr
Max speed: 14 knots
Range: Coastal area- 20 nm in winter, 15 nm in summer, in tropical zone upto 100 nm
Class Notation:
I +HULL + MACH
RO-RO PASSENGER SHIP
COASTAL AREA
+AUT-UMS, ICE CLASS 1D
Other important international regulations complied as per Danish Maritime Authority
Main engine:
Maker: Cummins
Model: QSK19 MCRs
Number: Two
Output: 375 kw each
Speed: 1800rpm
Propulsion & Steering System:
Maker: Schottel
Model: STP 0330 FP
Steering Type: SCHOTTEL SST 602
Number: Two (aft & forward)
Upper and lower gear box type: SCHOTTEL CYCLO-PALLOID-TYPE GEAR DIAMETER
Gear ratio: 4.042:1
Shafting Arrangement on each propulsion: 2 X Carden Shaft,1x Solid Intermediate Shaft,1x Elastic Coupling
Shafting Length: 4000 Mm (each propulsion)
Propellers
Material: G-CuAI10Fe5Ni5-C (CU 3)
Type: Azimuth propeller
Maker: Schottel
Number: Two (Aft & forward)
Fixed pitch (push/pull system)
Diameter: 1250 mm
Speed: 445 rpm to get 11 knot vessel speed.
Place of Photo: Uden for Hundested Havn. 55.961°, 11.834°
65m Landing Craft for Dubai, United Arab Emirates made by Western Marine
Bilal9
ELITE MEMBER
- Joined
- Feb 4, 2014
- Messages
- 26,569
- Reaction score
- 9
- Country
- Location
recently CDDL and Western Marine has signed agreement of co-operation in various field including .... ahem
I know.
But those are gonna be larger I believe.
Bilal9
ELITE MEMBER
- Joined
- Feb 4, 2014
- Messages
- 26,569
- Reaction score
- 9
- Country
- Location
Bangladesh Pharmaceutical Industry 101
Md. Tashnim
Insight
July 27, 2017
According to a forecast by Quintiles IMS Holding, global spending on prescription medicines will reach nearly $1.5 trillion by 2021. Reuter reported in December last year, that figure, based on wholesale pricing, is up nearly $370 billion from estimated 2016 spending. One of the major drivers of the growth, according to the report, is narrowing the gap in medicine usage between developed and developing markets.
A recent research from BMI Research suggests, Bangladesh’s pharmaceutical market will continue to post relatively high growth rates in 2017, an estimated +11.1% in local currency terms and +8.1% in US dollar terms from BDT 190bn (USD 2.4bn) in 2016 to BDT 211bn (USD 2.6bn) in 2017. by 2020 the market is estimated to be USD 3.369bn.
The Pharmaceutical industry is one of the most dynamic and technologically advanced industries in Bangladesh. Imports are restricted for locally manufactured drugs giving the industry protection from external competition.
Over the past decades, it has seen phenomenal growth, currently contributing to almost one percent of GDP and is expected to grow significantly in the coming years. Bangladesh is experiencing a consistent increase in healthcare expenditure, mostly out of pocket, which currently stands at almost three percent of GDP. Estimates suggest the domestic market will grow further in the coming years.
This overview is prepared based on the available secondary data. Data sources used to prepare this story are DGDA, export.gov, BMI research, Bangladesh pharmaceuticals, and healthcare report and Quintiles IMS among others.
- Bangladesh pharmaceuticals industry is controlled by two regulatory bodies: Directorate General of Drug Administration (DGDA) and Pharmacy Council of Bangladesh (PCB).
- DGDA is the national drug regulatory authority under Ministry of Health and Family Welfare and regulates all activities related to import and export of raw materials, packaging materials, production, sale, pricing, licensing, registration of all kinds of medicine.
- PCB was established under the Pharmacy Ordinance Act in 1976 to control the pharmacy practice in Bangladesh. They have put restrictions on the production of 1,700 non-essential or harmful drugs and strict price controls on some 117 principal medicines.
- Bangladesh currently has around 150 pharmaceutical companies in operation
- The top 20 companies generate 85 percent of the revenue.
- According to export.gov, the top ten manufacturers by share of market revenue are as follows: Square (19 percent), Incepta (9.5 percent), Beximco (9 percent), Opsonin (5 percent), Renata (4.9 percent), Eskayef (4.7 percent), ACI (4.3 percent), ACME (4.1 percent), Aristopharma (4 percent), and Drug International (3.7 percent)
- About 90 percent of market share is dominated by local manufacturers dominate the industry while multinationals hold 10 percent.
- Bangladesh pharmaceutical industry satisfies 97% of domestic demands and the rest 3% of drugs are imports. Imports are restricted for drugs that are locally manufactured and available.
- Bangladesh pharmaceutical industry mostly produces generic drugs, in fact, Bangladesh is now a hub for affordable and high-quality generic medicines. About 85 percent of the drugs sold in Bangladesh are generic and 15 percent are patented drugs.
- Bangladesh manufactures more than 450 generic drugs for 5,300 registered brands, which have 8,300 different forms of dosages and strengths.
- 30 pharmaceutical companies export to 113 countries. Not only tablets, capsules, and syrups but also specialized products like HFA inhalers, CFC inhalers, suppositories, nasal sprays, injectable, IV infusions are exported from this industry
- Free from the obligations to implement patents and data protection for pharmaceutical products until 2033.
- According to EPB, Bangladesh exported $37.9 million (about Tk.3.0 billion) worth of drugs in the fiscal year 2015 -2016 (EPB)
- In an industrial park, which is situated at Baushia, Gajaria, Munshiganj and will cost 4.39 billion BDT, 42 Active Pharmaceutical Ingredients manufacturing industrial units will be set up there.
- Sales of generic drugs in Bangladesh is estimated to reach BDT 30,300 crore by 2024.
- Generic drugs exported from Bangladesh amounts to 25% of the worldwide pharmaceutical sales.
Bilal9
ELITE MEMBER
- Joined
- Feb 4, 2014
- Messages
- 26,569
- Reaction score
- 9
- Country
- Location
Wooden Custom Door and Door Frame Manufacturing Company in Bangladesh (Wood World)
They custom-developed the manufacturing process and machines by themselves (including the brush sanders, quadra planers and Numeric Control engravers seen in the following videos). As well as 48-Hour Kiln-drier rapid seasoning for Teak and Mahogany wood used in their machining process for custom doors and frames.
They custom-developed the manufacturing process and machines by themselves (including the brush sanders, quadra planers and Numeric Control engravers seen in the following videos). As well as 48-Hour Kiln-drier rapid seasoning for Teak and Mahogany wood used in their machining process for custom doors and frames.
Bilal9
ELITE MEMBER
- Joined
- Feb 4, 2014
- Messages
- 26,569
- Reaction score
- 9
- Country
- Location
Her chirpy and overly active presentation at WMShL was giving me a bit of a headache, but the subject matter is engaging nonetheless...and loved the hot pink hardhat...
Dredgers built at Karnaphuli Shipyard
Last edited:
Bilal9
ELITE MEMBER
- Joined
- Feb 4, 2014
- Messages
- 26,569
- Reaction score
- 9
- Country
- Location
Walton launches ioniser, inverter, smart ACs for summer
Published: March 08, 2018 14:55:59
Picture shows a Walton AC with inverter technology.
Electronics giant Walton has launched some unique featured air-conditioners (ACs) including ioniser, inverter, and smart ACs aiming to help people get rid of the sweltering summer heat.
Engineer Md. Ishaque Rony, chief operating officer of Walton AC, said this year Walton is manufacturing and marketing its latest IoT (Internet of Things) based smart air-conditioners with power efficient inverter technology’s compressor in the local market, says a media release.
Users of the Walton ‘Smart AC’ would be able to monitor the power consumption units, daily or monthly electricity bill of it, compressor's condition like overload or normal, power connection situation like on or off, and high or low voltage supply to it through their mobile phones from any corner of the world, Ishaque said.
According to the official, the AC with ioniser technology will work as a 'Lung Doctor' ensuring pure and healthy air across the room through filtering dusts, smoke, bacteria, and odour from room.
The Walton AC with inverter technology’s compressor would consume 50 per cent lesser electricity than the general technology’s ACs, Ishaque noted.
In Bangladesh, about 0.30 million units of air-conditioners are sold out annually, the Walton official said reminding that the demand for AC geos up during the summer.
The Walton ACs come with six-month replacement guarantee and up to eight years guarantee-facility on its compressor. Besides, buyers can avail 36-month EMI facility during purchases.
Published: March 08, 2018 14:55:59
Electronics giant Walton has launched some unique featured air-conditioners (ACs) including ioniser, inverter, and smart ACs aiming to help people get rid of the sweltering summer heat.
Engineer Md. Ishaque Rony, chief operating officer of Walton AC, said this year Walton is manufacturing and marketing its latest IoT (Internet of Things) based smart air-conditioners with power efficient inverter technology’s compressor in the local market, says a media release.
Users of the Walton ‘Smart AC’ would be able to monitor the power consumption units, daily or monthly electricity bill of it, compressor's condition like overload or normal, power connection situation like on or off, and high or low voltage supply to it through their mobile phones from any corner of the world, Ishaque said.
According to the official, the AC with ioniser technology will work as a 'Lung Doctor' ensuring pure and healthy air across the room through filtering dusts, smoke, bacteria, and odour from room.
The Walton AC with inverter technology’s compressor would consume 50 per cent lesser electricity than the general technology’s ACs, Ishaque noted.
In Bangladesh, about 0.30 million units of air-conditioners are sold out annually, the Walton official said reminding that the demand for AC geos up during the summer.
The Walton ACs come with six-month replacement guarantee and up to eight years guarantee-facility on its compressor. Besides, buyers can avail 36-month EMI facility during purchases.
Bilal9
ELITE MEMBER
- Joined
- Feb 4, 2014
- Messages
- 26,569
- Reaction score
- 9
- Country
- Location
Meghna Shipbuilders and other larger builders in NarayanGanj and KeraniGanj area build and launch these riverine tankers almost on a monthly basis....long video, skip to 5:00.
Bus Manufacturing at Shohagh SCANIA JV using Solidworks CAD/CAM software
Bus Manufacturing at Shohagh SCANIA JV using Solidworks CAD/CAM software
Bilal9
ELITE MEMBER
- Joined
- Feb 4, 2014
- Messages
- 26,569
- Reaction score
- 9
- Country
- Location
Modern insulin to be made locally
Novo Nordisk to transfer tech to Eskayef as they sign MoU
Simeen Hossain, managing director of Eskayef Pharmaceuticals, and Anand Shetty, managing director of Novo Nordisk Bangladesh, sign an MoU at Sonargaon hotel yesterday. Zahid Malik, state minister for health; Mikael Hemniti Winther, Danish ambassador to Bangladesh; Sebnem Avsar Tuna, corporate vice-president for Novo Nordisk Oceania and Southeast Asia; Latifur Rahman, chairman and CEO of Transcom Group, and Mustafizur Rahman, director general of the Directorate General of Drug Administration, were also present. Photo: Star
Star Business Report
Novo Nordisk, the world's biggest insulin maker, has teamed up with local Eskayef Pharmaceuticals to set up a state-of-the-art manufacturing facility in what can be viewed as a pat on the back to Bangladesh's pharmaceutical sector.
The Danish pharmaceutical giant has six such production facilities outside of its home country but this is the first time that it has partnered with a foreign company to set up a plant.
“It is a great moment of honour for Eskayef Pharmaceuticals and I think even more importantly for Bangladesh,” said Latifur Rahman, chairman and chief executive of Transcom Group, the parent company of Eskayef Pharmaceuticals. Rahman's comment came at an agreement signing ceremony between the two companies, held yesterday at the capital's Pan Pacific Sonargaon hotel.
The memorandum of understanding entails transfer of Novo Nordisk's proprietary state-of-the-art technology to produce human and modern insulin in cartridges to Bangladesh.
The production facility, which will be set up at a cost of Tk 300 crore, is expected to be complete in three years.
The Danish pharmaceutical giant in partnership with Eskayef has been manufacturing human insulin vials in Bangladesh since 2012, but pen-filled modern insulin products are still imported from Denmark.
It is one of the defining moments for Novo Nordisk in Bangladesh, said Sebnem Avsar Tuna, corporate vice-president for Novo Nordisk Oceania and Southeast Asia regions.
“And it is because Eskayef is a trusted partner for us,” she said.
Once the facility, which will be housed at Eskayef's existing site in Tongi, is up and running, Bangladesh will be able to cut its reliance on imports.
Under the arrangement not only the technology will be transferred but also the organisational values, skills, education, training and knowledge, said Mikael Hemniti Winther, the Danish ambassador to Bangladesh.
“There are seven million or more diabetic patients in Bangladesh and today we signed a commitment for them,” said Lars Bo Smidt, corporate vice-president for finance and operations at Novo Nordisk's Africa, Asia, Middle East and Oceania operations.
Novo Nordisk undertakes a due and diligent process before investing in a country.
“Today, we invest in Bangladesh. We will invest money, resources and technology. We will bring the best people here to work with the health care sector and the government,” he added.
Zahid Malik, state minister for health and family welfare, said he hopes the prices will be within the means of the common people and the quality one of the best in the world.
As many as 69 lakh people are living with diabetes in Bangladesh and the figure will double to 1.37 crore by 2045, according to the International Diabetes Federation.
“I think it is much more than that. It would be around 10 million now,” Malik said.
It is well-known that Bangladesh has seven million diabetic patients, but there are many patients who are unaware that they have diabetes, according to Malik.
Many people are dying because of diabetes-related complications. “It has a big impact on families, the health sector and also the productivity of the country,” he added.
Sayef Uddin, secretary general of the Diabetic Association of Bangladesh (DAB), said the association has always felt that pharmaceutical products should be available in the country and must be of high quality, convenient and also affordable. “I am sure this venture will go in that way,” he said.
The signing of the agreement is the testimony to the development of Bangladesh's drug industry, said AK Azad Khan, president of the DAB.
The step taken by Novo Nordisk and Eskayef is a remarkable one and Bangladesh's pharmaceutical sector would reap benefit from it, said Mustafizur Rahman, director-general of the Directorate General of Drug Administration.
The country has the potential to become a major partner of the global pharmaceutical industry, said SM Shafiuzzaman, general secretary of the Bangladesh Association of Pharmaceutical Industries.
“It will serve Bangladesh's citizens and patients,” said Transcom chief Rahman, adding that the plant could even explore export potential.
Simeen Hossain, managing director and chief executive of Eskayef Pharmaceuticals, and Anand Shetty, managing director of Novo Nordisk Bangladesh, signed the agreement on behalf of the two parties. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care.
This heritage has given the company experience and capabilities to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases.
Since 1958, Novo Nordisk has been working in Bangladesh, bringing in high-quality diabetes products, raising awareness among the public and training health professionals.
Over the years, Eskayef has emerged as one of the leading pharmaceutical companies in Bangladesh.
Its state-of-the-art manufacturing facility has been approved by stringent global regulators, including UK MHRA, European Medicines Agency, TGA Australia, VMD UK and the Unicef.
Eskayef is growing globally and is already exporting its products to different countries in Asia, Africa, Europe and Australia.
Transcom Distribution Company Ltd distributes Novo Nordisk's insulin products across the country. Roxana Quader, additional secretary of the health and family welfare ministry, was also present at the event.
Novo Nordisk to transfer tech to Eskayef as they sign MoU
Simeen Hossain, managing director of Eskayef Pharmaceuticals, and Anand Shetty, managing director of Novo Nordisk Bangladesh, sign an MoU at Sonargaon hotel yesterday. Zahid Malik, state minister for health; Mikael Hemniti Winther, Danish ambassador to Bangladesh; Sebnem Avsar Tuna, corporate vice-president for Novo Nordisk Oceania and Southeast Asia; Latifur Rahman, chairman and CEO of Transcom Group, and Mustafizur Rahman, director general of the Directorate General of Drug Administration, were also present. Photo: Star
Star Business Report
Novo Nordisk, the world's biggest insulin maker, has teamed up with local Eskayef Pharmaceuticals to set up a state-of-the-art manufacturing facility in what can be viewed as a pat on the back to Bangladesh's pharmaceutical sector.
The Danish pharmaceutical giant has six such production facilities outside of its home country but this is the first time that it has partnered with a foreign company to set up a plant.
“It is a great moment of honour for Eskayef Pharmaceuticals and I think even more importantly for Bangladesh,” said Latifur Rahman, chairman and chief executive of Transcom Group, the parent company of Eskayef Pharmaceuticals. Rahman's comment came at an agreement signing ceremony between the two companies, held yesterday at the capital's Pan Pacific Sonargaon hotel.
The memorandum of understanding entails transfer of Novo Nordisk's proprietary state-of-the-art technology to produce human and modern insulin in cartridges to Bangladesh.
The production facility, which will be set up at a cost of Tk 300 crore, is expected to be complete in three years.
The Danish pharmaceutical giant in partnership with Eskayef has been manufacturing human insulin vials in Bangladesh since 2012, but pen-filled modern insulin products are still imported from Denmark.
It is one of the defining moments for Novo Nordisk in Bangladesh, said Sebnem Avsar Tuna, corporate vice-president for Novo Nordisk Oceania and Southeast Asia regions.
“And it is because Eskayef is a trusted partner for us,” she said.
Once the facility, which will be housed at Eskayef's existing site in Tongi, is up and running, Bangladesh will be able to cut its reliance on imports.
Under the arrangement not only the technology will be transferred but also the organisational values, skills, education, training and knowledge, said Mikael Hemniti Winther, the Danish ambassador to Bangladesh.
“There are seven million or more diabetic patients in Bangladesh and today we signed a commitment for them,” said Lars Bo Smidt, corporate vice-president for finance and operations at Novo Nordisk's Africa, Asia, Middle East and Oceania operations.
Novo Nordisk undertakes a due and diligent process before investing in a country.
“Today, we invest in Bangladesh. We will invest money, resources and technology. We will bring the best people here to work with the health care sector and the government,” he added.
Zahid Malik, state minister for health and family welfare, said he hopes the prices will be within the means of the common people and the quality one of the best in the world.
As many as 69 lakh people are living with diabetes in Bangladesh and the figure will double to 1.37 crore by 2045, according to the International Diabetes Federation.
“I think it is much more than that. It would be around 10 million now,” Malik said.
It is well-known that Bangladesh has seven million diabetic patients, but there are many patients who are unaware that they have diabetes, according to Malik.
Many people are dying because of diabetes-related complications. “It has a big impact on families, the health sector and also the productivity of the country,” he added.
Sayef Uddin, secretary general of the Diabetic Association of Bangladesh (DAB), said the association has always felt that pharmaceutical products should be available in the country and must be of high quality, convenient and also affordable. “I am sure this venture will go in that way,” he said.
The signing of the agreement is the testimony to the development of Bangladesh's drug industry, said AK Azad Khan, president of the DAB.
The step taken by Novo Nordisk and Eskayef is a remarkable one and Bangladesh's pharmaceutical sector would reap benefit from it, said Mustafizur Rahman, director-general of the Directorate General of Drug Administration.
The country has the potential to become a major partner of the global pharmaceutical industry, said SM Shafiuzzaman, general secretary of the Bangladesh Association of Pharmaceutical Industries.
“It will serve Bangladesh's citizens and patients,” said Transcom chief Rahman, adding that the plant could even explore export potential.
Simeen Hossain, managing director and chief executive of Eskayef Pharmaceuticals, and Anand Shetty, managing director of Novo Nordisk Bangladesh, signed the agreement on behalf of the two parties. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care.
This heritage has given the company experience and capabilities to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases.
Since 1958, Novo Nordisk has been working in Bangladesh, bringing in high-quality diabetes products, raising awareness among the public and training health professionals.
Over the years, Eskayef has emerged as one of the leading pharmaceutical companies in Bangladesh.
Its state-of-the-art manufacturing facility has been approved by stringent global regulators, including UK MHRA, European Medicines Agency, TGA Australia, VMD UK and the Unicef.
Eskayef is growing globally and is already exporting its products to different countries in Asia, Africa, Europe and Australia.
Transcom Distribution Company Ltd distributes Novo Nordisk's insulin products across the country. Roxana Quader, additional secretary of the health and family welfare ministry, was also present at the event.
